ClinicalTrials.gg
CompletedNCT01074294STEP-AUpdated Feb 2, 2023Results posted

Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder

A Phase 2 interventional study of OPDC-34712 and Placebo in Attention Deficit Hyperactivity Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 35 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2023-02-02.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
740
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 25 studies in Attention Deficit Disorder with Hyperactivity by Otsuka Holdings Co., Ltd. — 5 open to participants now, 5 under way, 5 of them phase 3. Attention Deficit Disorder with Hyperactivity · Otsuka Holdings Co., Ltd..

Enrollment
Largest of 25
740 · median 180
Started
2010
the only one that year
Phase 2
5 of 25
none open now
Registered
1st of 25
by date

Among the 25 studies in Attention Deficit Disorder with Hyperactivity by Otsuka Holdings Co., Ltd., this one has the largest enrollment, is the only one that started in 2010, is one of 5 in phase 2, and was the 1st registered.

Attention Deficit Disorder with Hyperactivity

1,818 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

5 of the 25 studies in Attention Deficit Disorder with Hyperactivity by Otsuka Holdings Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Attention Deficit Disorder with Hyperactivity by Otsuka Holdings Co., Ltd., or all of them as a file.
02

Study summary

This study tests the effects of an investigational antipsychotic drug (called OPC-34712) in adults with attention deficit hyperactivity disorder (ADHD) when taken with an approved stimulant medication to explore a possible impact on sleep, quality of life and cognitive function.

03

Conditions studied

  • Attention Deficit Hyperactivity Disorder

Keywords

  • Inattention
  • Hyperactivity
  • Impulsivity
  • Distractibility
  • Procrastination
  • Disorganized
  • ADHD
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female outpatients 18 to 55 years of age, inclusive, at the time of .
  • Participants with a primary , fourth edition, text revision (DSM-IV-TR) diagnosis of ADHD (including inattentive, hyperactive, and combined subtypes) as confirmed by the Conners' Adult ADHD diagnostic interview (CAADID). Participants may have received prior treatment for adult ADHD, may be currently receiving treatment for adult ADHD at screening, or may be treatment-naive.
  • Participants willing to discontinue all prohibited psychotropic medication starting from the time of signing the informed consent and during the study period.

Exclusion criteria

Exclusion Criteria:

  • Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving study drug.
  • Participants with an adequate response, as determined by the investigator, to any stimulant taken for the treatment of adult ADHD after 18 years of age.
  • Participants with a current Axis II () diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal, or histrionic personality disorder.
  • Participants who participated in a clinical trial within the last 180 days or who participated in more than two clinical trials within the past year.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
740 participants (actual)

Study arms

  • Experimental
    Phase A (Single-blind Prospective Treatment Phase): Placebo + Stimulant

    Participants received single-blind matching-placebo tablets along with open-label stimulant determined by the investigator, once daily for 5 weeks. Once assigned to a stimulant by the investigator, participants remained on the same stimulant for the duration of the trial. Participants who met eligibility criteria i.e., who received prior treatment for adult ADHD and treatment-naïve participants were included in this arm group. Participants with incomplete response at the end of Phase A (Week 5) entered Phase B and rest of the participants continued to Phase A+.

    Drug: Placebo · Drug: Stimulant Therapy

  • Experimental
    Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant

    Participants with incomplete response (with a \> 0% and \< 30% reduction in ADHD Symptoms Total Score {18 items} between the baseline of Phase A and the end of prospective treatment { Week 5} as measured by the CAARS-O:SV { Conners' Adult ADHD Rating Scale-Observer: Screening Version}, and a CAARS-O:SV ADHD Symptoms Total Score {18 items} of ≥ 24 at Week 5, and a clinical global impression - improvement scale (CGI-I) score of 3 or 4 at Week 5) at the end of Phase A (Week 5), received Brexpiprazole 2 milligram (mg) tablet along with stimulant determined by the investigator, once daily for 6 weeks (up to Week 11).

    Drug: OPDC-34712 · Drug: Stimulant Therapy

  • Placebo comparator
    Phase B (Double-blind Randomization Phase): Placebo + Stimulant

    Participants with incomplete response (with a \> 0% and \< 30% reduction in ADHD Symptoms Total Score {18 items} between the Baseline of Phase A and the end of prospective treatment { Week 5} as measured by the CAARS-O:SV, and a CAARS-O:SV ADHD Symptoms Total Score {18 items} of ≥ 24 at Week 5, and a CGI-I score of 3 or 4 at Week 5) at the end of Phase A (Week 5), received matching-placebo tablets along with stimulant determined by the investigator, once daily for 6 weeks (up to Week 11).

    Drug: Placebo · Drug: Stimulant Therapy

  • Experimental
    Phase A+ (Single-blind Phase A Responders and Non-responders): Placebo + Stimulant

    Participants with response (with a ≥ 30% reduction in ADHD Symptoms Total Score {18 items} between Baseline of Phase A and the end of prospective treatment { Week 5} as measured by the CAARS-O:SV, or a CAARS-O:SV ADHD Symptoms Total Score {18 items} of \< 24 at Week 5, or a CGI-I score of \< 3 at Week 5) and non-response (with deterioration or no change in ADHD symptoms at Week 5) at the end of Phase A (Week 5), received single-blind matching-placebo tablets along with open-label stimulant determined by the investigator, once daily for an additional 6 weeks (up to Week 11).

    Drug: Placebo · Drug: Stimulant Therapy

Interventions

  • DrugBrexpiprazoleStudies of BrexpiprazoleBrexpiprazole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    OPDC-34712 tablets, daily, Orally.

    Also known as: Brexpiprazole

  • DrugPlacebo

    Matching-placebo tablets, daily, Orally.

  • DrugStimulant Therapy

    Mixed amphetamine salts or Dexmethylphenidate hydrochloride (HCL) or Methylphenidate HCl or Lisdexamfetamine dimesylate as per standard of care.

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline (End of Phase A) in the CAARS-O:SV ADHD Symptoms Total Score (18 Items) to End of Phase B

    The CAARS-O:SV is a 30 items scale with 3 subscales: Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Inattentive Symptoms (9 items), DSM- IV Hyperactive/Impulsive Symptoms (9 items), and DSM-IV ADHD Index (12 items). Total ADHD Symptoms Score (18 items) consisted of the combined score for the inattentive symptoms and hyperactive/impulsive symptoms subscales and is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) for a total score ranging from of 0 to 54, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The Mixed model repeated measures (MMRM) model was used for analysis.

    Time frame: Baseline [end of Phase A (Week 5)] to Week 11

Secondary outcomes

  1. Change From Baseline (End of Phase A) in Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS) Total Score to End of Phase B

    WRAADDS is used to measure the severity of symptoms in adults with ADHD. This structured interview consists of 28 items in 7 psychopathologic domains, which were rated by a clinical expert on a 0 to 2-point Likert scale. The psychopathologic 7 domains are inattention (6 items), impulsivity (3 items), and hyperactivity (3 items), disorganization (5 items), temper (3 items), affective lability (4 items), and emotional over-reactivity (4 items). The scale rated individual items from 0 to 2 (0=not present, 1=mild, 2=clearly present) and summarized each of the 7 categories on a 0-to-4 scale (0=none, 1=mild, 2=moderate, 3=quite a bit, 4=very much). The WRAADDS total score is defined as sum of all 28 item sub scores (range 0 - 56), higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The analysis of covariance (ANCOVA) method was used for analysis.

    Time frame: Baseline [end of Phase A (Week 5)] to Week 11

  2. Change From Baseline (End of Phase A) in Sleep Improvement Measured by Insomnia Severity Index (ISI) Total Score to End of Phase B

    The ISI is self-report instrument that has been validated specifically for measuring the perceived severity of insomnia. The scale was composed of a total of 7 items based on self-report questionnaire based on several indicators assessing the perceived severity of difficulties initiating sleep, staying asleep, and early morning awakenings, satisfaction with current sleep pattern, interference with daily functioning, noticeability of impairment attributed to the sleep problem, and degree of distress or concern caused by the sleep problem. Each item was rated on a scale from 0 (none) to 4 (higher score indicating greater impairment/concern). A total score ranging from 0 to 28 was calculated from the sum of the individual item scores, higher scores indicate increased severity of insomnia. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.

    Time frame: Baseline [end of Phase A (Week 5)] to Week 11

  3. Change From Baseline (End of Phase A) in Sleep Improvement Measured by ISI for Item 2 Score (Difficulty Staying Asleep) to End of Phase B

    The ISI is self-report instrument that has been validated specifically for measuring the perceived severity of insomnia. The scale was composed of a total of 7 items based on self-report questionnaire based on several indicators assessing the perceived severity of difficulties initiating sleep, staying asleep, and early morning awakenings, satisfaction with current sleep pattern, interference with daily functioning, noticeability of impairment attributed to the sleep problem, and degree of distress or concern caused by the sleep problem. Each item was rated on a scale from 0 (none) to 4 (higher score indicating greater impairment/concern). A total score ranging from 0 to 28 was calculated from the sum of the individual item scores, higher scores indicate increased severity of insomnia. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.

    Time frame: Baseline [end of Phase A (Week 5)] to Week 11

  4. Change From Baseline (End of Phase A) in the Spatial Working Memory (SWM) Between Errors 4-8 Boxes Test Score as Measured by Cambridge Neuropsychological Test Automated Battery (CANTAB) to End of Phase B

    ADHD was measured with the CANTAB. SWM test was one of the tasks of CANTAB, SWM measured the ability to retain spatial information and to manipulate remembered items in working memory. This test was sensitive measure of executive dysfunction. Participants search for colored tokens hidden inside boxes on screen by touching them. The critical instruction was that once token has been found inside box, no token was hidden inside that box again, so participants must not return to box where a token was found. The key measurement of the SWM task is the SWM Between Errors 4-8 Boxes, which measured the total number of times a participant revisits a box in which a token has previously been found is measured for the 4, 6, and 8-box stages. Total scores ranged from 0-153. A lower score indicated better performance. The ANCOVA model was used for analysis.

    Time frame: Baseline [end of Phase A (Week 5)] to Week 11

  5. Change From Baseline (End of Phase A) in CAARS-O:SV ADHD Symptoms Total Score (18 Items) to Each Time Point in Phase B Other Than Week 11

    The CAARS-O:SV is a 30 items scale with 3 subscales DSM-IV Inattentive Symptoms (9 items), DSM-IV Hyperactive/Impulsive Symptoms (9 items), and DSM-IV ADHD Index (12 items). Total ADHD Symptoms Score (18 items) consisted of the combined score for the inattentive symptoms and hyperactive/impulsive symptoms subscales and is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) for total score ranging from of 0 to 54, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.

    Time frame: Baseline [end of Phase A (Week 5)] to Weeks 6, 7, 8, 9 and 10

  6. Change From Baseline (End of Phase A) in CAARS-O:SV Inattentive Symptoms Subscale Score (9 Items) to Each Time Point in Phase B

    The CAARS-O:SV is a 30 items scale with 3 subscales DSM-IV Inattentive Symptoms (9 items), DSM-IV Hyperactive/Impulsive Symptoms (9 items), and DSM-IV ADHD Index (12 items). The inattentive symptoms subscale (9 items) is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) with total score ranging from 0 to 27, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.

    Time frame: Baseline [end of Phase A (Week 5)]; Weeks 6, 7, 8, 9, 10 and 11

  7. Change From Baseline (End of Phase A) in CAARS-O:SV Hyperactive/Impulsive Symptoms Subscale Score (9 Items) to Each Time Point in Phase B

    The CAARS-O:SV is a 30 items scale with 3 subscales DSM-IV Inattentive Symptoms (9 items), DSM-IV Hyperactive/Impulsive Symptoms (9 items), and DSM-IV ADHD Index (12 items). The hyperactive/impulsive Symptoms Subscale is (9 items) scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) with total score ranging from 0 to 27, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.

    Time frame: Baseline [end of Phase A (Week 5)]; Weeks 6, 7, 8, 9, 10 and 11

  8. Change From Baseline (End of Phase A) in CAARS-O:SV ADHD Index Score (12 Items) to Each Time Point in Phase B

    The CAARS-S:SV is a 30 items scale with 3 subscales inattention (9 items), hyperactivity-impulsivity (9 items), and ADHD index (12 items). The ADHD index score (12 items) is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) with total score ranging from 0 to 36, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.

    Time frame: Baseline [end of Phase A (Week 5)]; Weeks 6, 7, 8, 9, 10 and 11

  9. Change From Baseline (End of Phase A) to Weeks 7 and 9 in ISI Total Score

    The ISI is self-report instrument that has been validated specifically for measuring the perceived severity of insomnia. The scale was composed of a total of 7 items based on self-report questionnaire based on several indicators assessing the perceived severity of difficulties initiating sleep, staying asleep, and early morning awakenings, satisfaction with current sleep pattern, interference with daily functioning, noticeability of impairment attributed to the sleep problem, and degree of distress or concern caused by the sleep problem. Each item was rated on a scale from 0 (none) to 4 (higher score indicating greater impairment/concern). A total score ranging from 0 to 28 was calculated from the sum of the individual item scores, higher scores indicate increased severity of insomnia. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.

    Time frame: Baseline [end of Phase A (Week 5)]; Weeks 7 and 9

  10. Percentage of Participants With Categorical Change in Sleep Improvement Measured by Individual Scores for Items 1, 2, and 3 of the ISI at End of Phase B

    The ISI is self-report instrument that has been validated specifically for measuring the perceived severity of insomnia. The scale was composed of a total of 7 items based on self-report questionnaire based on several indicators assessing the perceived severity. difficulties initiating sleep, staying asleep, and early morning awakenings, satisfaction with current sleep pattern, interference with daily functioning, noticeability of impairment attributed to the sleep problem, and degree of distress or concern caused by the sleep problem. Each item was rated on a scale from 0 (none) to 4 (higher score indicating greater impairment/concern). A negative change from Baseline indicates improvement. The Cochran-Mantel-Haenszel model was used for analysis.

    Time frame: Baseline [(end of Phase A (Week 5)] to Weeks 7, 9 and 11

  11. Change From Baseline (End of Phase A) in Conners' Adult ADHD Rating Scale-Self-Report: Screening Version (CAARS-S:SV) ADHD Symptoms Total Score (18 Items) to Each Timepoint in Phase B

    The CAARS-S:SV is a self-reported 30 items scale with 3 subscales inattention (9 items), hyperactivity-impulsivity (9 items), and ADHD index (12 items). Total ADHD Symptoms Score (18 items) consisted of the combined score for the Inattentive Symptoms and Hyperactive/Impulsive Symptoms subscales and is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) for total score ranging from of 0 to 54, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.

    Time frame: Baseline [end of Phase A (Week 5)]; Weeks 6, 7, 8, 9, 10 and 11

  12. Change From Baseline (End of Phase A) in CAARS-S:SV Inattentive Symptoms Subscale Score (9 Items) to Each Timepoint in Phase B

    The CAARS-S:SV is a self-reported 30 items scale with 3 subscales inattention (9 items), hyperactivity-impulsivity (9 items), and ADHD index (12 items). The Inattentive Symptoms Subscale is (9 items) scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) with total score ranging from 0 to 27, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.

    Time frame: Baseline [end of Phase A (Week 5)]; Weeks 6, 7, 8, 9, 10 and 11

  13. Change From Baseline (End of Phase A) in CAARS-S:SV Hyperactive/Impulsive Symptoms Subscale Score (9 Items) to Each Timepoint in Phase B

    The CAARS-S:SV is a 30 items scale with 3 subscales inattention (9 items), hyperactivity-impulsivity (9 items), and ADHD index (12 items). The Hyperactive/Impulsive Symptoms Subscale is (9 items) scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) with total score ranging from 0 to 27, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.

    Time frame: Baseline [end of Phase A (Week 5)]; Weeks 6, 7, 8, 9, 10 and 11

  14. Change From Baseline (End of Phase A) in CAARS-S:SV ADHD Index Score (12 Items) to Each Timepoint in Phase B

    The CAARS-S:SV is a 30 items scale with 3 subscales inattention (9 items), hyperactivity-impulsivity (9 items), and ADHD index (12 items). The ADHD Index Subscale is (12 items) scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) with total score ranging from 0 to 36, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.

    Time frame: Baseline [end of Phase A (Week 5)]; Weeks 6, 7, 8, 9, 10 and 11

  15. Change From Baseline (End of Phase A) in Clinical Global Impression - Severity of Illness Scale (CGI-S) Score to Each Timepoint in Phase B

    The CGI-S is performed to rate the severity of a participant's condition on an 8-point scale ranging from 0 to 7 where 0=not assessed, 1=normal, not at all ill, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, and 7 = among the most extremely ill participants. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.

    Time frame: Baseline [end of Phase A (Week 5)]; Weeks 6, 7, 8, 9, 10 and 11

  16. Change From Baseline (End of Phase A) in the SWM Strategy 6-8 Boxes Test Score as Measured by CANTAB to End of Phase B

    The SWM test assesses the cognitive domain of executive function (high-level thinking and decision making). SWM task was SWM Strategy 6-8 Boxes, in which the total number of distinct boxes used by the participant to begin a new search for a token within the same problem was measured for the 6- and 8-box stages. The SWM strategy index of executive function represented the number of times a participant began a search with a different box. Participant was asked to find tokens in on-screen boxes and move them. Difficulty ranged from 4 to 8 box assessments. Strategy score was the number of unique boxes the participant searched in 6 and 8 box trials. 6 box trial scores ranged from 1 (1 box searched for all 6 tokens) to 6 (6 boxes searched for 6 tokens). 8 box trial score ranged from 1 (1 box searched) to 8 (8 boxes searched for 8 tokens). Total of the 2 trial scores ranged from 2 to 14. A lower score reflects better performance. The ANCOVA method was used for analysis.

    Time frame: Baseline [end of Phase A (Week 5)] to Week 11

  17. Change From Baseline (End of Phase A) in the SWM Within Errors 4-8 Boxes Test Score as Measured by CANTAB to End of Phase B

    Assessments were performed with CANTAB. SWM test assesses cognitive domain of executive function (high-level thinking and decision making). Participants search for colored tokens hidden inside boxes on screen by touching them. Critical instruction is that once a token has been found inside a box, there was never be a token hidden inside that box again, so participants must not return to a box where a token has been found. Within Errors 4-8 Boxes, which measured number of times a participant revisited a box that had already been found to be empty during the same search. Value was reported as total number of errors for 4-, 6-, and 8-box stages. Observed range for Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant is -8.00 to 6.00 (change from baseline) and for Phase B (Double-blind Randomization Phase): Placebo + Stimulant is -10.0 to 23.00 (change from baseline). A lower score reflects better performance. LOCF method was used to impute missing data.

    Time frame: Baseline [end of Phase A (Week 5)] to Week 11

  18. Change From Baseline (End of Phase A) in the Rapid Visual Information Processing (RVP) A Prime Test Score as Measured by CANTAB to End of Phase B

    Assessments were performed with the CANTAB. The RVP task tested continuous performance and visual sustained attention. In the center of the computer screen, digits from 2 to 9 appear inside a white box in pseudorandom order at a rate of 100 digits per minute. Participants must touch the press pad when they detect a series of target digit sequences (eg, 2-4-6, 4-6-8, 3-5-7) which appeared at a rate of 9 sequences every 100 numbers. Data from the RVP task were summarized in 3 ways: RVP A prime, RVP median response latency, and RVP total false alarms. RVP A prime was the signal detection measure of sensitivity to the target, regardless of response tendency (range 0.00 to 1.00; bad to good). In essence, this metric was a measure of how good the participant was at detecting target sequences. Higher scores indicated better performance. The ANCOVA method was used for analysis.

    Time frame: Baseline [end of Phase A (Week 5)] to Week 11

  19. Change From Baseline (End of Phase A) in the RVP Median Response Latency Score as Measured by CANTAB to End of Phase B

    Assessments were performed with CANTAB. RVP task tested continuous performance and visual sustained attention. In the center of computer screen, digits from 2 to 9 appear inside white box in pseudorandom order at a rate of 100 digits per minute. Participants must touch press pad when they detect a series of target digit sequences (eg, 2-4-6, 4-6-8, 3-5-7) which appeared at a rate of 9 sequences every 100 numbers. Data from RVP task were summarized in 3 ways: RVP A prime, RVP median response latency, and RVP total false alarms. Median response latency was measured during the assessed part of test (7-minute continuous part of test after initial 2 minutes training phase). Observed range for Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant is -338 to 282.0 (change from baseline) and for Phase B (Double-blind Randomization Phase): Placebo + Stimulant is -134 to 235.0 (change from baseline). Lower scores indicate better performance. ANCOVA method was used for analysis.

    Time frame: Baseline [end of Phase A (Week 5)] to Week 11

  20. Change From Baseline (End of Phase A) in RVP Total False Alarms Score as Measured by CANTAB to End of Phase B

    RVP task tested continuous performance and visual sustained attention. In center of computer screen, digits from 2- 9 appear inside a white box in pseudorandom order at a rate of 100 digits per minute. Participants must touch press pad when they detect a series of target digit sequences (e.g., 2-4-6, 4-6-8, 3-5-7) which appeared at a rate of 9 sequences every 100 numbers. Data from RVP task were summarized in 3 ways: RVP A prime, RVP median response latency, and RVP total false alarms. False alarms were determined from number of times that participants responded outside response window of a target sequence during assessed part of test. Observed range for Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant is -26.0 to 13.00 (change from baseline) and for Phase B (Double-blind Randomization Phase): Placebo + Stimulant is -25.0 to 144.0 (change from baseline). Lower scores indicate better performance. ANCOVA model was used for analysis.

    Time frame: Baseline [end of Phase A (Week 5)] to Week 11

  21. Change From Baseline (End of Phase A) in the Stop Signal Task (SST) Stop Signal Reaction Time (SSRT) Score as Measured by CANTAB to End of Phase B

    In SST, an arrow pointing either left or right is displayed on computer screen. Participant responded to arrow by pressing corresponding button (i.e., left or right) on press pad. If an audio tone is presented when arrow is displayed, participant inhibited response. Proportion of successful stops, and median reaction time on Go trials was measured. SST SSRT was an estimate of length of time between go stimulus and stop stimulus at which participant was able to successfully inhibit response on 50% of trials and calculated from SST reaction time on Go trials measure and SST stop signal delay (SSD) 50% measure as \[reaction time on Go trials\] - \[SSD (50%)\], where SSD (50%) measure was calculated as arithmetic mean of measured SSD, or failed stop reaction time, from completed assessment stop trials. Observed change from baseline range for Phase B: Brexpiprazole + Stimulant: -204 to 237.0 and for Phase B: Placebo + Stimulant: -176 to 113.0. Lower scores indicate better performance.

    Time frame: Baseline [end of Phase A (Week 5)] to Week 11

  22. Change From Baseline (End of Phase A) in the SST Proportion of Successful Stops Score as Measured by CANTAB to End of Phase B

    SST measures participants ability to inhibit a response. An arrow pointing either left or right is displayed on computer screen. Participant responded to arrow by pressing corresponding button (i.e., left or right) on press pad. If an audio tone is presented when arrow is displayed, participant inhibited his/her response. Proportion of successful stops, and median reaction time on Go trials was measured. The proportion of successful stops is calculated as the number of times that the participant stopped successfully, divided by the total number of stop signals. Observed range for Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant: -0.40 to 0.40 (change from baseline) and for Phase B (Double-blind Randomization Phase): Placebo + Stimulant: -0.38 to 0.38 (change from baseline). Higher scores indicate a positive outcome for proportion of successful stops.

    Time frame: Baseline [end of Phase A (Week 5)] to Week 11

  23. Change From Baseline (End of Phase A) in SST Median Reaction Time Score on Go Trials as Measured by CANTAB to End of Phase B

    SST measures participants ability to inhibit a response. An arrow pointing either left or right is displayed on computer screen. Participant responded to arrow by pressing corresponding button (i.e., left or right) on press pad. If an audio tone is presented when arrow is displayed, participant inhibited his/her response. Proportion of successful stops, and median reaction time on Go trials was measured. The median reaction time on Go trials is the median of the reaction time assessed on Go trials to which the participant responded correctly. Observed range for Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant: -277 to 266.0 (change from baseline) and for Phase B (Double-blind Randomization Phase): Placebo + Stimulant: -462 to 358.0 (change from baseline). Lower scores indicate better performance.

    Time frame: Baseline [end of Phase A (Week 5)] to Week 11

  24. Change From Baseline (End of Phase A) in WRAADDS Attention + Organization Subscale Score to End of Phase B

    WRAADDS is used to measure the severity of symptoms in adults with ADHD. This structured interview consists of 28 items in 7 psychopathologic domains, which were rated by a clinical expert on a 0 to 2-point Likert scale. The psychopathologic 7 domains are inattention (6 items), impulsivity (3 items), and hyperactivity (3 items), disorganization (5 items), temper (3 items), affective lability (4 items), and emotional over-reactivity (4 items). The scale rated individual items from 0 to 2 (0=not present, 1=mild, 2=clearly present). The score for attention + organization subscale score ranges from 0-22, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The ANCOVA method was used for analysis.

    Time frame: Baseline [end of Phase A (Week 5)] to Week 11

  25. Change From End of Phase A (Week 5 Visit) to End of Phase B (Week 11 Visit) in WRAADDS Hyperactivity + Impulsivity Subscale Score to End of Phase B

    WRAADDS is used to measure the severity of symptoms in adults with ADHD. This structured interview consists of 28 items in 7 psychopathologic domains, which were rated by a clinical expert on a 0 to 2-point Likert scale. The psychopathologic 7 domains are inattention (6 items), impulsivity (3 items), and hyperactivity (3 items), disorganization (5 items), temper (3 items), affective lability (4 items), and emotional over-reactivity (4 items). The scale rated individual items from 0 to 2 (0=not present, 1=mild, 2=clearly present). The score for hyperactivity + impulsivity subscale score ranges from 0-12, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The ANCOVA model was used for analysis.

    Time frame: Baseline [end of Phase A (Week 5)] to Week 11

  26. Change From Baseline (End of Phase A) in WRAADDS Temper + Mood Lability + Emotional Over-reactivity Subscale Score to End of Phase B

    WRAADDS is used to measure the severity of symptoms in adults with ADHD. This structured interview consists of 28 items in 7 psychopathologic domains, which were rated by a clinical expert on a 0 to 2-point Likert scale. The psychopathologic 7 domains are inattention (6 items), impulsivity (3 items), and hyperactivity (3 items), disorganization (5 items), temper (3 items), affective lability (4 items), and emotional over-reactivity (4 items). The scale rated individual items from 0 to 2 (0=not present, 1=mild, 2=clearly present). The score for temper + mood Lability + emotional over-reactivity subscale score ranges from 0-22, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The ANCOVA model was used for analysis.

    Time frame: Baseline [end of Phase A (Week 5)] to Week 11

  27. Mean CGI-I Score at Each Timepoint in Phase B

    The CGI-I permits a global evaluation of the participant's improvement over time. The CGI-I is a 8-point scale ranging from 0 to 7 where 0=not assessed, 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse and 7=very much worse. The CGI-I is completed by the clinician and assesses the participant's improvement relative to the symptoms at Baseline. The Cochran-Mantel-Haenszel model was used for analysis.

    Time frame: Weeks 6, 7, 8, 9, 10 and 11

  28. Percentage of Participants With CAARS-O:SV ADHD Symptoms Response Rate in Phase B

    Response was defined as ≥ 30% reduction in CAARS-O:SV ADHD Symptoms Total Score (18 items) from end of Phase A (Week 5 visit). An 18-item ADHD Symptoms Total Score consisted of the combined score for the Inattentive Symptoms and Hyperactive/Impulsive Symptoms subscales. The CAARS-O:SV was designed to measure a cross-section of ADHD-related symptoms and behaviors in adults using observer and self-report scales. Total ADHD Symptoms Score (18 items) consisted of the combined score for the inattentive symptoms and hyperactive/impulsive symptoms subscales and is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) for a total score ranging from of 0 to 54, higher scores indicate worsening of symptoms.

    Time frame: Weeks 6, 7, 8, 9, 10 and 11

  29. Percentage of Participants With CAARS-O:SV ADHD Symptoms Remission Rate in Phase B

    Remission was defined as CAARS-O:SV ADHD Symptoms Total Score (18 items) of ≤ 18 and a ≥ 30% reduction in CAARS-O:SV ADHD Symptoms Total Score (18 items) from end of Phase A (Week 5 visit). An 18-item ADHD Symptoms Total Score consisted of the combined score for the Inattentive Symptoms and Hyperactive/Impulsive Symptoms subscales. The CAARS-O:SV was designed to measure a cross-section of ADHD-related symptoms and behaviors in adults using observer and self-report scales. Total ADHD Symptoms Score (18 items) consisted of the combined score for the inattentive symptoms and hyperactive/impulsive symptoms subscales and is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) for a total score ranging from of 0 to 54, higher scores indicate worsening of symptoms. The Cochran-Mantel-Haenszel model was used for analysis.

    Time frame: Weeks 6, 7, 8, 9, 10 and 11

  30. Percentage of Participants With CAARS-S:SV ADHD Symptoms Response Rate in Phase B

    Response was defined as ≥ 30% reduction in CAARS-S:SV ADHD Symptoms Total Score (18 items) from end of Phase A (Week 5 visit). The CAARS-S:SV is a 30 items scale with 3 subscales inattention (9 items), hyperactivity-impulsivity (9 items), and ADHD index (12 items). Total ADHD Symptoms Score (18 items) consisted of the combined score for the Inattentive Symptoms and Hyperactive/Impulsive Symptoms subscales is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) for total score ranging from of 0 to 54, higher scores indicate worsening of symptoms. The Cochran-Mantel-Haenszel model was used for analysis.

    Time frame: Weeks 6, 7, 8, 9, 10 and 11

  31. Percentage of Participants With CAARS-S:SV ADHD Symptoms Remission Rate in Phase B

    Remission was defined as CAARS-S:SV ADHD Symptoms Total Score (18 items) of ≤ 18 and a ≥ 30% reduction in CAARS-S:SV ADHD Symptoms Total Score (18 items) from end of Phase A (Week 5 visit). The CAARS-S:SV is a 30 items scale with 3 subscales inattention (9 items), hyperactivity-impulsivity (9 items), and ADHD index (12 items). Total ADHD Symptoms Score (18 items) consisted of the combined score for the Inattentive Symptoms and Hyperactive/Impulsive Symptoms subscales is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) for total score ranging from of 0 to 54, higher scores indicate worsening of symptoms. The Cochran-Mantel-Haenszel model was used for analysis.

    Time frame: Weeks 6, 7, 8, 9, 10 and 11

  32. Percentage of Participants With CGI-I Response Rate in Phase B

    Response was defined as a CGI-I score of 1 or 2 (very much improved or much improved). The CGI-I permits a global evaluation of the participant's improvement over time. The CGI-I is a 8-point scale ranging from 0 to 7 where 0=not assessed, 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse and 7=very much worse. The Cochran-Mantel-Haenszel model was used for analysis.

    Time frame: Weeks 6, 7, 8, 9, 10 and 11

07

Results

Posted Feb 2, 2023

Participant flow

This study was conducted at 37 sites in United States from 16 Mar 2010 to 20 Jun 2011.

Phase A (Day 1 to Week 5)
Participant flow — Phase A (Day 1 to Week 5)
MilestonePhase A (Single-blind Prospective Treatment Phase): Placebo + StimulantPhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + StimulantPhase A+ (Single-blind Phase A Responders and Non-responders): Placebo + Stimulant
Started740000
Analyzed for safety733000
Completed574000
Not completed166000
Withdrew: Lost to follow-up16000
Withdrew: Adverse event51000
Withdrew: Protocol specified withdrawal criteria47000
Withdrew: Withdrawn from participation by the investigator3000
Withdrew: Withdrawal by subject32000
Withdrew: Protocol deviation10000
Withdrew: Participants not dosed7000
Phase B and Phase A+ (Week 6 to Week 11)
Participant flow — Phase B and Phase A+ (Week 6 to Week 11)
MilestonePhase A (Single-blind Prospective Treatment Phase): Placebo + StimulantPhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + StimulantPhase A+ (Single-blind Phase A Responders and Non-responders): Placebo + Stimulant
Started015580339
Analyzed for safety015580235
Completed014670314
Not completed091025
Withdrew: Lost to follow-up02211
Withdrew: Adverse event0238
Withdrew: Protocol-specified withdrawal criteria0200
Withdrew: Withdrawal by subject0224
Withdrew: Protocol violation0032
Withdrew: Lack of efficacy0100

Outcome measures

PrimaryMean Change From Baseline (End of Phase A) in the CAARS-O:SV ADHD Symptoms Total Score (18 Items) to End of Phase B

The CAARS-O:SV is a 30 items scale with 3 subscales: Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Inattentive Symptoms (9 items), DSM- IV Hyperactive/Impulsive Symptoms (9 items), and DSM-IV ADHD Index (12 items). Total ADHD Symptoms Score (18 items) consisted of the combined score for the inattentive symptoms and hyperactive/impulsive symptoms subscales and is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) for a total score ranging from of 0 to 54, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The Mixed model repeated measures (MMRM) model was used for analysis.

Time frame:
Baseline [end of Phase A (Week 5)] to Week 11
Reported as:
Least squares mean · score on a scale
Mean Change From Baseline (End of Phase A) in the CAARS-O:SV ADHD Symptoms Total Score (18 Items) to End of Phase B
score on a scalePhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + Stimulant
Mean Change From Baseline (End of Phase A) in the CAARS-O:SV ADHD Symptoms Total Score (18 Items) to End of Phase B-9.02 ± 0.77-9.71 ± 1.06
Statistical analysis
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.5845 (The p-value was derived using MMRM method with treatment, trial center, visit week, and treatment by visit week interaction as class effects and Week 5 value as covariate.) · Mean difference (final values): 0.69 · 95% CI -1.80 to 3.19The difference between Least Squares (LS) means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
SecondaryChange From Baseline (End of Phase A) in Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS) Total Score to End of Phase B

WRAADDS is used to measure the severity of symptoms in adults with ADHD. This structured interview consists of 28 items in 7 psychopathologic domains, which were rated by a clinical expert on a 0 to 2-point Likert scale. The psychopathologic 7 domains are inattention (6 items), impulsivity (3 items), and hyperactivity (3 items), disorganization (5 items), temper (3 items), affective lability (4 items), and emotional over-reactivity (4 items). The scale rated individual items from 0 to 2 (0=not present, 1=mild, 2=clearly present) and summarized each of the 7 categories on a 0-to-4 scale (0=none, 1=mild, 2=moderate, 3=quite a bit, 4=very much). The WRAADDS total score is defined as sum of all 28 item sub scores (range 0 - 56), higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The analysis of covariance (ANCOVA) method was used for analysis.

Time frame:
Baseline [end of Phase A (Week 5)] to Week 11
Reported as:
Least squares mean · score on a scale
Change From Baseline (End of Phase A) in Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS) Total Score to End of Phase B
score on a scalePhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + Stimulant
Change From Baseline (End of Phase A) in Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS) Total Score to End of Phase B-3.93 ± 0.42-3.84 ± 0.56
Statistical analysis
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · ANCOVA · p = 0.8832 (The p-value was derived using ANCOVA model with treatment and trial center as main effects and Week 5 value as covariate.) · Mean difference (final values): -0.09 · 95% CI -1.37 to 1.18The difference between LS means derived from the ANCOVA model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
SecondaryChange From Baseline (End of Phase A) in Sleep Improvement Measured by Insomnia Severity Index (ISI) Total Score to End of Phase B

The ISI is self-report instrument that has been validated specifically for measuring the perceived severity of insomnia. The scale was composed of a total of 7 items based on self-report questionnaire based on several indicators assessing the perceived severity of difficulties initiating sleep, staying asleep, and early morning awakenings, satisfaction with current sleep pattern, interference with daily functioning, noticeability of impairment attributed to the sleep problem, and degree of distress or concern caused by the sleep problem. Each item was rated on a scale from 0 (none) to 4 (higher score indicating greater impairment/concern). A total score ranging from 0 to 28 was calculated from the sum of the individual item scores, higher scores indicate increased severity of insomnia. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.

Time frame:
Baseline [end of Phase A (Week 5)] to Week 11
Reported as:
Least squares mean · score on a scale
Change From Baseline (End of Phase A) in Sleep Improvement Measured by Insomnia Severity Index (ISI) Total Score to End of Phase B
score on a scalePhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + Stimulant
Change From Baseline (End of Phase A) in Sleep Improvement Measured by Insomnia Severity Index (ISI) Total Score to End of Phase B-1.05 ± 0.41-1.62 ± 0.56
Statistical analysis
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.3864 (The p-value was derived using MMRM method with treatment, trial center, visit week, and treatment by visit week interaction as class effects and Week 5 value as covariate.) · Mean difference (final values): 0.57 · 95% CI -0.72 to 1.86The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
SecondaryChange From Baseline (End of Phase A) in Sleep Improvement Measured by ISI for Item 2 Score (Difficulty Staying Asleep) to End of Phase B

The ISI is self-report instrument that has been validated specifically for measuring the perceived severity of insomnia. The scale was composed of a total of 7 items based on self-report questionnaire based on several indicators assessing the perceived severity of difficulties initiating sleep, staying asleep, and early morning awakenings, satisfaction with current sleep pattern, interference with daily functioning, noticeability of impairment attributed to the sleep problem, and degree of distress or concern caused by the sleep problem. Each item was rated on a scale from 0 (none) to 4 (higher score indicating greater impairment/concern). A total score ranging from 0 to 28 was calculated from the sum of the individual item scores, higher scores indicate increased severity of insomnia. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.

Time frame:
Baseline [end of Phase A (Week 5)] to Week 11
Reported as:
Least squares mean · score on a scale
Change From Baseline (End of Phase A) in Sleep Improvement Measured by ISI for Item 2 Score (Difficulty Staying Asleep) to End of Phase B
score on a scalePhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + Stimulant
Change From Baseline (End of Phase A) in Sleep Improvement Measured by ISI for Item 2 Score (Difficulty Staying Asleep) to End of Phase B-0.04 ± 0.08-0.37 ± 0.10
Statistical analysis
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.0061 (The p value was derived using MMRM method with treatment, trial center, visit week, and treatment by visit week interaction as class effects and Week 5 value as covariate.) · Mean difference (final values): 0.34 · 95% CI 0.10 to 0.58The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
SecondaryChange From Baseline (End of Phase A) in the Spatial Working Memory (SWM) Between Errors 4-8 Boxes Test Score as Measured by Cambridge Neuropsychological Test Automated Battery (CANTAB) to End of Phase B

ADHD was measured with the CANTAB. SWM test was one of the tasks of CANTAB, SWM measured the ability to retain spatial information and to manipulate remembered items in working memory. This test was sensitive measure of executive dysfunction. Participants search for colored tokens hidden inside boxes on screen by touching them. The critical instruction was that once token has been found inside box, no token was hidden inside that box again, so participants must not return to box where a token was found. The key measurement of the SWM task is the SWM Between Errors 4-8 Boxes, which measured the total number of times a participant revisits a box in which a token has previously been found is measured for the 4, 6, and 8-box stages. Total scores ranged from 0-153. A lower score indicated better performance. The ANCOVA model was used for analysis.

Time frame:
Baseline [end of Phase A (Week 5)] to Week 11
Reported as:
Least squares mean · score on a scale
Change From Baseline (End of Phase A) in the Spatial Working Memory (SWM) Between Errors 4-8 Boxes Test Score as Measured by Cambridge Neuropsychological Test Automated Battery (CANTAB) to End of Phase B
score on a scalePhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + Stimulant
Change From Baseline (End of Phase A) in the Spatial Working Memory (SWM) Between Errors 4-8 Boxes Test Score as Measured by Cambridge Neuropsychological Test Automated Battery (CANTAB) to End of Phase B0.10 ± 0.67-0.31 ± 0.90
Statistical analysis
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · ANCOVA · p = 0.6932 (The p-value was derived from ANCOVA model, with treatment and trial center as main effects and Week 5 value as covariate.) · Mean difference (final values): 0.41 · 95% CI -1.64 to 2.46This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
SecondaryChange From Baseline (End of Phase A) in CAARS-O:SV ADHD Symptoms Total Score (18 Items) to Each Time Point in Phase B Other Than Week 11

The CAARS-O:SV is a 30 items scale with 3 subscales DSM-IV Inattentive Symptoms (9 items), DSM-IV Hyperactive/Impulsive Symptoms (9 items), and DSM-IV ADHD Index (12 items). Total ADHD Symptoms Score (18 items) consisted of the combined score for the inattentive symptoms and hyperactive/impulsive symptoms subscales and is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) for total score ranging from of 0 to 54, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.

Time frame:
Baseline [end of Phase A (Week 5)] to Weeks 6, 7, 8, 9 and 10
Reported as:
Least squares mean · score on a scale
Change From Baseline (End of Phase A) in CAARS-O:SV ADHD Symptoms Total Score (18 Items) to Each Time Point in Phase B Other Than Week 11
score on a scalePhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + Stimulant
Change at Week 6-3.82 ± 0.49-4.62 ± 0.64
Change at Week 7-5.54 ± 0.58-6.21 ± 0.78
Change at Week 8-6.37 ± 0.68-6.99 ± 0.92
Change at Week 9-7.58 ± 0.71-8.14 ± 0.96
Change at Week 10-7.71 ± 0.76-9.11 ± 1.04
Statistical analysis
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.2781 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.81 · 95% CI -0.66 to 2.28The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.4673 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.67 · 95% CI -1.15 to 2.49The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.5719 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.62 · 95% CI -1.54 to 2.79The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.6262 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.56 · 95% CI -1.70 to 2.83The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.2638 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 1.40 · 95% CI -1.06 to 3.87The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
SecondaryChange From Baseline (End of Phase A) in CAARS-O:SV Inattentive Symptoms Subscale Score (9 Items) to Each Time Point in Phase B

The CAARS-O:SV is a 30 items scale with 3 subscales DSM-IV Inattentive Symptoms (9 items), DSM-IV Hyperactive/Impulsive Symptoms (9 items), and DSM-IV ADHD Index (12 items). The inattentive symptoms subscale (9 items) is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) with total score ranging from 0 to 27, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.

Time frame:
Baseline [end of Phase A (Week 5)]; Weeks 6, 7, 8, 9, 10 and 11
Reported as:
Least squares mean · score on a scale
Change From Baseline (End of Phase A) in CAARS-O:SV Inattentive Symptoms Subscale Score (9 Items) to Each Time Point in Phase B
score on a scalePhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + Stimulant
Change at Week 6-2.00 ± 0.32-2.43 ± 0.41
Change at Week 7-2.94 ± 0.36-3.20 ± 0.48
Change at Week 8-3.14 ± 0.40-3.42 ± 0.54
Change at Week 9-3.74 ± 0.42-4.04 ± 0.57
Change at Week 10-3.95 ± 0.45-4.85 ± 0.62
Change at Week 11-4.58 ± 0.44-4.86 ± 0.60
Statistical analysis
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.3804 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.42 · 95% CI -0.52 to 1.37The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.6422 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.26 · 95% CI -0.86 to 1.39The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.6707 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.28 · 95% CI -1.00 to 1.55The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.6638 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.30 · 95% CI -1.04 to 1.64The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.2252 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.90 · 95% CI -0.56 to 2.36The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.6970 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.28 · 95% CI -1.14 to 1.70The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
SecondaryChange From Baseline (End of Phase A) in CAARS-O:SV Hyperactive/Impulsive Symptoms Subscale Score (9 Items) to Each Time Point in Phase B

The CAARS-O:SV is a 30 items scale with 3 subscales DSM-IV Inattentive Symptoms (9 items), DSM-IV Hyperactive/Impulsive Symptoms (9 items), and DSM-IV ADHD Index (12 items). The hyperactive/impulsive Symptoms Subscale is (9 items) scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) with total score ranging from 0 to 27, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.

Time frame:
Baseline [end of Phase A (Week 5)]; Weeks 6, 7, 8, 9, 10 and 11
Reported as:
Least squares mean · score on a scale
Change From Baseline (End of Phase A) in CAARS-O:SV Hyperactive/Impulsive Symptoms Subscale Score (9 Items) to Each Time Point in Phase B
score on a scalePhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + Stimulant
Change at Week 6-1.88 ± 0.29-2.11 ± 0.38
Change at Week 7-2.66 ± 0.32-2.94 ± 0.43
Change at Week 8-3.29 ± 0.36-3.48 ± 0.49
Change at Week 9-3.90 ± 0.39-4.01 ± 0.53
Change at Week 10-3.83 ± 0.41-4.17 ± 0.55
Change at Week 11-4.51 ± 0.42-4.80 ± 0.58
Statistical analysis
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.6008 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.23 · 95% CI -0.64 to 1.11The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.5859 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.28 · 95% CI -0.72 to 1.27The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.7406 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.19 · 95% CI -0.96 to 1.34The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.8568 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.12 · 95% CI -1.14 to 1.37The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.6044 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.34 · 95% CI -0.96 to 1.64The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.6772 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.29 · 95% CI -1.08 to 1.66The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
SecondaryChange From Baseline (End of Phase A) in CAARS-O:SV ADHD Index Score (12 Items) to Each Time Point in Phase B

The CAARS-S:SV is a 30 items scale with 3 subscales inattention (9 items), hyperactivity-impulsivity (9 items), and ADHD index (12 items). The ADHD index score (12 items) is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) with total score ranging from 0 to 36, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.

Time frame:
Baseline [end of Phase A (Week 5)]; Weeks 6, 7, 8, 9, 10 and 11
Reported as:
Least squares mean · score on a scale
Change From Baseline (End of Phase A) in CAARS-O:SV ADHD Index Score (12 Items) to Each Time Point in Phase B
score on a scalePhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + Stimulant
Change at Week 6-2.06 ± 0.34-2.20 ± 0.44
Change at Week 7-3.47 ± 0.41-3.38 ± 0.55
Change at Week 8-4.01 ± 0.44-3.80 ± 0.59
Change at Week 9-4.32 ± 0.46-4.78 ± 0.62
Change at Week 10-4.65 ± 0.47-5.23 ± 0.64
Change at Week 11-5.60 ± 0.48-5.94 ± 0.66
Statistical analysis
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.7881 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.14 · 95% CI -0.87 to 1.15The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.8841 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): -0.09 · 95% CI -1.38 to 1.19The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.7589 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): -0.22 · 95% CI -1.61 to 1.17The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.5375 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.46 · 95% CI -1.01 to 1.93The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.4456 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.58 · 95% CI -0.92 to 2.08The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.6670 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.34 · 95% CI -1.21 to 1.89The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
SecondaryChange From Baseline (End of Phase A) to Weeks 7 and 9 in ISI Total Score

The ISI is self-report instrument that has been validated specifically for measuring the perceived severity of insomnia. The scale was composed of a total of 7 items based on self-report questionnaire based on several indicators assessing the perceived severity of difficulties initiating sleep, staying asleep, and early morning awakenings, satisfaction with current sleep pattern, interference with daily functioning, noticeability of impairment attributed to the sleep problem, and degree of distress or concern caused by the sleep problem. Each item was rated on a scale from 0 (none) to 4 (higher score indicating greater impairment/concern). A total score ranging from 0 to 28 was calculated from the sum of the individual item scores, higher scores indicate increased severity of insomnia. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.

Time frame:
Baseline [end of Phase A (Week 5)]; Weeks 7 and 9
Reported as:
Least squares mean · score on a scale
Change From Baseline (End of Phase A) to Weeks 7 and 9 in ISI Total Score
score on a scalePhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + Stimulant
Change at Week 7-0.81 ± 0.33-0.83 ± 0.44
Change at Week 9-0.99 ± 0.37-1.48 ± 0.49
Statistical analysis
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.9708 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.02 · 95% CI -0.97 to 1.01The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.3970 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.49 · 95% CI -0.65 to 1.63The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
SecondaryPercentage of Participants With Categorical Change in Sleep Improvement Measured by Individual Scores for Items 1, 2, and 3 of the ISI at End of Phase B

The ISI is self-report instrument that has been validated specifically for measuring the perceived severity of insomnia. The scale was composed of a total of 7 items based on self-report questionnaire based on several indicators assessing the perceived severity. difficulties initiating sleep, staying asleep, and early morning awakenings, satisfaction with current sleep pattern, interference with daily functioning, noticeability of impairment attributed to the sleep problem, and degree of distress or concern caused by the sleep problem. Each item was rated on a scale from 0 (none) to 4 (higher score indicating greater impairment/concern). A negative change from Baseline indicates improvement. The Cochran-Mantel-Haenszel model was used for analysis.

Time frame:
Baseline [(end of Phase A (Week 5)] to Weeks 7, 9 and 11
Reported as:
Number · percentage of participants
Percentage of Participants With Categorical Change in Sleep Improvement Measured by Individual Scores for Items 1, 2, and 3 of the ISI at End of Phase B
percentage of participantsPhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + Stimulant
Difficulty Falling Asleep: Week 733.632.4
Difficulty Falling Asleep: Week 933.337.7
Difficulty Falling Asleep: Week 1135.339.0
Difficulty Staying Asleep: Week 726.835.1
Difficulty Staying Asleep: Week 925.333.8
Difficulty Staying Asleep: Week 1124.737.7
Waking Up Too Early: Week 728.225.7
Waking Up Too Early: Week 930.726.0
Waking Up Too Early: Week 1129.328.6
Statistical analysis
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.9568 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 1.01 · 95% CI 0.68 to 1.50The difference between LS means derived from the Cochran-Mantel-Haenszel (CMH) model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.6308 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 0.91 · 95% CI 0.63 to 1.31The difference between LS means derived from the Cochran-Mantel-Haenszel (CMH) model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.6698 (The p-value was derived from CMH general association test controlling for study center) · Risk ratio (rr): 0.92 · 95% CI 0.64 to 1.32The difference between LS means derived from the Cochran-Mantel-Haenszel (CMH) model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.2012 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 0.76 · 95% CI 0.50 to 1.15The difference between LS means derived from the Cochran-Mantel-Haenszel (CMH) model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.2365 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 0.78 · 95% CI 0.52 to 1.16The difference between LS means derived from the Cochran-Mantel-Haenszel (CMH) model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.0312 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 0.65 · 95% CI 0.44 to 0.96The difference between LS means derived from the Cochran-Mantel-Haenszel (CMH) model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.6408 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 1.12 · 95% CI 0.69 to 1.81The difference between LS means derived from the Cochran-Mantel-Haenszel (CMH) model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.3467 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 1.24 · 95% CI 0.79 to 1.96The difference between LS means derived from the Cochran-Mantel-Haenszel (CMH) model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.9437 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 1.02 · 95% CI 0.65 to 1.59The difference between LS means derived from the Cochran-Mantel-Haenszel (CMH) model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
SecondaryChange From Baseline (End of Phase A) in Conners' Adult ADHD Rating Scale-Self-Report: Screening Version (CAARS-S:SV) ADHD Symptoms Total Score (18 Items) to Each Timepoint in Phase B

The CAARS-S:SV is a self-reported 30 items scale with 3 subscales inattention (9 items), hyperactivity-impulsivity (9 items), and ADHD index (12 items). Total ADHD Symptoms Score (18 items) consisted of the combined score for the Inattentive Symptoms and Hyperactive/Impulsive Symptoms subscales and is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) for total score ranging from of 0 to 54, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.

Time frame:
Baseline [end of Phase A (Week 5)]; Weeks 6, 7, 8, 9, 10 and 11
Reported as:
Least squares mean · score on a scale
Change From Baseline (End of Phase A) in Conners' Adult ADHD Rating Scale-Self-Report: Screening Version (CAARS-S:SV) ADHD Symptoms Total Score (18 Items) to Each Timepoint in Phase B
score on a scalePhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + Stimulant
Change at Week 6-1.75 ± 0.58-2.16 ± 0.75
Change at Week 7-3.01 ± 0.65-3.47 ± 0.87
Change at Week 8-4.15 ± 0.68-4.08 ± 0.92
Change at Week 9-4.24 ± 0.73-5.23 ± 0.99
Change at Week 10-4.63 ± 0.77-6.11 ± 1.04
Change at Week 11-5.38 ± 0.78-6.33 ± 1.07
Statistical analysis
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.6357 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.41 · 95% CI -1.30 to 2.12The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.6536 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.46 · 95% CI -1.56 to 2.48The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.9475 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): -0.07 · 95% CI -2.20 to 2.06The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.3973 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.99 · 95% CI -1.31 to 3.29The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.2336 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 1.47 · 95% CI -0.96 to 3.91The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.4553 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.95 · 95% CI -1.55 to 3.44The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
SecondaryChange From Baseline (End of Phase A) in CAARS-S:SV Inattentive Symptoms Subscale Score (9 Items) to Each Timepoint in Phase B

The CAARS-S:SV is a self-reported 30 items scale with 3 subscales inattention (9 items), hyperactivity-impulsivity (9 items), and ADHD index (12 items). The Inattentive Symptoms Subscale is (9 items) scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) with total score ranging from 0 to 27, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.

Time frame:
Baseline [end of Phase A (Week 5)]; Weeks 6, 7, 8, 9, 10 and 11
Reported as:
Least squares mean · score on a scale
Change From Baseline (End of Phase A) in CAARS-S:SV Inattentive Symptoms Subscale Score (9 Items) to Each Timepoint in Phase B
score on a scalePhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + Stimulant
Change at Week 6-0.87 ± 0.33-1.16 ± 0.43
Change at Week 7-1.64 ± 0.37-1.62 ± 0.49
Change at Week 8-2.08 ± 0.40-1.93 ± 0.54
Change at Week 9-2.08 ± 0.42-2.42 ± 0.56
Change at Week 10-2.43 ± 0.43-2.84 ± 0.58
Change at Week 11-2.54 ± 0.43-3.10 ± 0.59
Statistical analysis
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.5647 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.29 · 95% CI -0.70 to 1.27The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.9739 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): -0.02 · 95% CI -1.15 to 1.12The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.8077 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): -0.15 · 95% CI -1.40 to 1.09The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.6119 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.34 · 95% CI -0.98 to 1.65The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.5513 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.41 · 95% CI -0.94 to 1.76The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.4185 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.57 · 95% CI -0.81 to 1.95The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
SecondaryChange From Baseline (End of Phase A) in CAARS-S:SV Hyperactive/Impulsive Symptoms Subscale Score (9 Items) to Each Timepoint in Phase B

The CAARS-S:SV is a 30 items scale with 3 subscales inattention (9 items), hyperactivity-impulsivity (9 items), and ADHD index (12 items). The Hyperactive/Impulsive Symptoms Subscale is (9 items) scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) with total score ranging from 0 to 27, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.

Time frame:
Baseline [end of Phase A (Week 5)]; Weeks 6, 7, 8, 9, 10 and 11
Reported as:
Least squares mean · score on a scale
Change From Baseline (End of Phase A) in CAARS-S:SV Hyperactive/Impulsive Symptoms Subscale Score (9 Items) to Each Timepoint in Phase B
score on a scalePhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + Stimulant
Change at Week 6-0.91 ± 0.32-1.06 ± 0.41
Change at Week 7-1.38 ± 0.35-1.88 ± 0.47
Change at Week 8-2.09 ± 0.36-2.20 ± 0.47
Change at Week 9-2.18 ± 0.39-2.87 ± 0.52
Change at Week 10-2.21 ± 0.41-3.33 ± 0.55
Change at Week 11-2.86 ± 0.42-3.31 ± 0.57
Statistical analysis
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.7556 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.15 · 95% CI -0.80 to 1.09The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.3710 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.50 · 95% CI -0.60 to 1.59The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.8464 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.11 · 95% CI -0.99 to 1.21The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.2664 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.69 · 95% CI -0.53 to 1.91The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.0876 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 1.13 · 95% CI -0.17 to 2.42The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.5119 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.44 · 95% CI -0.89 to 1.77The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
SecondaryChange From Baseline (End of Phase A) in CAARS-S:SV ADHD Index Score (12 Items) to Each Timepoint in Phase B

The CAARS-S:SV is a 30 items scale with 3 subscales inattention (9 items), hyperactivity-impulsivity (9 items), and ADHD index (12 items). The ADHD Index Subscale is (12 items) scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) with total score ranging from 0 to 36, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.

Time frame:
Baseline [end of Phase A (Week 5)]; Weeks 6, 7, 8, 9, 10 and 11
Reported as:
Least squares mean · score on a scale
Change From Baseline (End of Phase A) in CAARS-S:SV ADHD Index Score (12 Items) to Each Timepoint in Phase B
score on a scalePhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + Stimulant
Change at Week 6-1.09 ± 0.37-1.16 ± 0.48
Change at Week 7-1.86 ± 0.42-2.13 ± 0.55
Change at Week 8-2.69 ± 0.44-2.43 ± 0.59
Change at Week 9-3.07 ± 0.46-3.00 ± 0.61
Change at Week 10-3.42 ± 0.47-3.56 ± 0.63
Change at Week 11-4.05 ± 0.48-3.90 ± 0.65
Statistical analysis
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.8986 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.07 · 95% CI -1.03 to 1.18The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.6850 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.26 · 95% CI -1.02 to 1.55The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.7108 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): -0.26 · 95% CI -1.61 to 1.10The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.9236 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): -0.07 · 95% CI -1.50 to 1.36The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.8576 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.13 · 95% CI -1.35 to 1.61The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.8483 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): -0.15 · 95% CI -1.67 to 1.37The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
SecondaryChange From Baseline (End of Phase A) in Clinical Global Impression - Severity of Illness Scale (CGI-S) Score to Each Timepoint in Phase B

The CGI-S is performed to rate the severity of a participant's condition on an 8-point scale ranging from 0 to 7 where 0=not assessed, 1=normal, not at all ill, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, and 7 = among the most extremely ill participants. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.

Time frame:
Baseline [end of Phase A (Week 5)]; Weeks 6, 7, 8, 9, 10 and 11
Reported as:
Least squares mean · score on a scale
Change From Baseline (End of Phase A) in Clinical Global Impression - Severity of Illness Scale (CGI-S) Score to Each Timepoint in Phase B
score on a scalePhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + Stimulant
Change at Week 6-0.75 ± 0.06-0.71 ± 0.08
Change at Week 7-0.92 ± 0.07-0.88 ± 0.09
Change at Week 8-1.03 ± 0.07-0.97 ± 0.10
Change at Week 9-1.16 ± 0.08-1.10 ± 0.11
Change at Week 10-1.17 ± 0.08-1.28 ± 0.11
Change at Week 11-1.31 ± 0.09-1.37 ± 0.12
Statistical analysis
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.6976 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): -0.04 · 95% CI -0.22 to 0.15The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.6986 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): -0.04 · 95% CI -0.25 to 0.17The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.6507 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): -0.06 · 95% CI -0.30 to 0.19The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.6550 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): -0.06 · 95% CI -0.32 to 0.20The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.3959 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.11 · 95% CI -0.15 to 0.38The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Mixed Models Analysis · p = 0.6763 (The p-value was derived using MMRM method with treatment, study center, visit week, and treatment by visit week interaction as class effects, and week 5 value as covariate.) · Mean difference (final values): 0.06 · 95% CI -0.23 to 0.35The difference between LS means derived from the MMRM model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
SecondaryChange From Baseline (End of Phase A) in the SWM Strategy 6-8 Boxes Test Score as Measured by CANTAB to End of Phase B

The SWM test assesses the cognitive domain of executive function (high-level thinking and decision making). SWM task was SWM Strategy 6-8 Boxes, in which the total number of distinct boxes used by the participant to begin a new search for a token within the same problem was measured for the 6- and 8-box stages. The SWM strategy index of executive function represented the number of times a participant began a search with a different box. Participant was asked to find tokens in on-screen boxes and move them. Difficulty ranged from 4 to 8 box assessments. Strategy score was the number of unique boxes the participant searched in 6 and 8 box trials. 6 box trial scores ranged from 1 (1 box searched for all 6 tokens) to 6 (6 boxes searched for 6 tokens). 8 box trial score ranged from 1 (1 box searched) to 8 (8 boxes searched for 8 tokens). Total of the 2 trial scores ranged from 2 to 14. A lower score reflects better performance. The ANCOVA method was used for analysis.

Time frame:
Baseline [end of Phase A (Week 5)] to Week 11
Reported as:
Least squares mean · score on a scale
Change From Baseline (End of Phase A) in the SWM Strategy 6-8 Boxes Test Score as Measured by CANTAB to End of Phase B
score on a scalePhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + Stimulant
Change From Baseline (End of Phase A) in the SWM Strategy 6-8 Boxes Test Score as Measured by CANTAB to End of Phase B0.15 ± 0.21-0.12 ± 0.28
Statistical analysis
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · ANCOVA · p = 0.4089 (The p-value was derived from ANCOVA model, with treatment and study center as main effects and week 5 value as covariate, is used for change from week 5 comparisons.) · Mean difference (final values): 0.27 · 95% CI -0.37 to 0.91The difference between LS means derived from the ANCOVA model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
SecondaryChange From Baseline (End of Phase A) in the SWM Within Errors 4-8 Boxes Test Score as Measured by CANTAB to End of Phase B

Assessments were performed with CANTAB. SWM test assesses cognitive domain of executive function (high-level thinking and decision making). Participants search for colored tokens hidden inside boxes on screen by touching them. Critical instruction is that once a token has been found inside a box, there was never be a token hidden inside that box again, so participants must not return to a box where a token has been found. Within Errors 4-8 Boxes, which measured number of times a participant revisited a box that had already been found to be empty during the same search. Value was reported as total number of errors for 4-, 6-, and 8-box stages. Observed range for Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant is -8.00 to 6.00 (change from baseline) and for Phase B (Double-blind Randomization Phase): Placebo + Stimulant is -10.0 to 23.00 (change from baseline). A lower score reflects better performance. LOCF method was used to impute missing data.

Time frame:
Baseline [end of Phase A (Week 5)] to Week 11
Reported as:
Least squares mean · score on a scale
Change From Baseline (End of Phase A) in the SWM Within Errors 4-8 Boxes Test Score as Measured by CANTAB to End of Phase B
score on a scalePhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + Stimulant
Change From Baseline (End of Phase A) in the SWM Within Errors 4-8 Boxes Test Score as Measured by CANTAB to End of Phase B0.00 ± 0.160.30 ± 0.22
Statistical analysis
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · ANCOVA · p = 0.2331 (The p-value was derived from ANCOVA model, with treatment and study center as main effects and week 5 value as covariate, is used for change from week 5 comparisons.) · Mean difference (final values): -0.30 · 95% CI -0.80 to 0.20Week 11 data is included here. The planned sample size of 225 participants (150 in brexipiprazole arm and 75 in the placebo arm) yielded at least 80% power to detect effects at a 2-tailed significance level of 0.05 using a two-sided z-test.
SecondaryChange From Baseline (End of Phase A) in the Rapid Visual Information Processing (RVP) A Prime Test Score as Measured by CANTAB to End of Phase B

Assessments were performed with the CANTAB. The RVP task tested continuous performance and visual sustained attention. In the center of the computer screen, digits from 2 to 9 appear inside a white box in pseudorandom order at a rate of 100 digits per minute. Participants must touch the press pad when they detect a series of target digit sequences (eg, 2-4-6, 4-6-8, 3-5-7) which appeared at a rate of 9 sequences every 100 numbers. Data from the RVP task were summarized in 3 ways: RVP A prime, RVP median response latency, and RVP total false alarms. RVP A prime was the signal detection measure of sensitivity to the target, regardless of response tendency (range 0.00 to 1.00; bad to good). In essence, this metric was a measure of how good the participant was at detecting target sequences. Higher scores indicated better performance. The ANCOVA method was used for analysis.

Time frame:
Baseline [end of Phase A (Week 5)] to Week 11
Reported as:
Least squares mean · score on a scale
Change From Baseline (End of Phase A) in the Rapid Visual Information Processing (RVP) A Prime Test Score as Measured by CANTAB to End of Phase B
score on a scalePhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + Stimulant
Change From Baseline (End of Phase A) in the Rapid Visual Information Processing (RVP) A Prime Test Score as Measured by CANTAB to End of Phase B0.00 ± 0.000.01 ± 0.00
Statistical analysis
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · ANCOVA · p = 0.0670 (The p-value was derived from ANCOVA model, with treatment and study center as main effects and week 5 value as covariate, is used for change from week 5 comparisons.) · Mean difference (final values): -0.01 · 95% CI -0.01 to 0.00The difference between LS means derived from the ANCOVA model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
SecondaryChange From Baseline (End of Phase A) in the RVP Median Response Latency Score as Measured by CANTAB to End of Phase B

Assessments were performed with CANTAB. RVP task tested continuous performance and visual sustained attention. In the center of computer screen, digits from 2 to 9 appear inside white box in pseudorandom order at a rate of 100 digits per minute. Participants must touch press pad when they detect a series of target digit sequences (eg, 2-4-6, 4-6-8, 3-5-7) which appeared at a rate of 9 sequences every 100 numbers. Data from RVP task were summarized in 3 ways: RVP A prime, RVP median response latency, and RVP total false alarms. Median response latency was measured during the assessed part of test (7-minute continuous part of test after initial 2 minutes training phase). Observed range for Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant is -338 to 282.0 (change from baseline) and for Phase B (Double-blind Randomization Phase): Placebo + Stimulant is -134 to 235.0 (change from baseline). Lower scores indicate better performance. ANCOVA method was used for analysis.

Time frame:
Baseline [end of Phase A (Week 5)] to Week 11
Reported as:
Least squares mean · score on a scale
Change From Baseline (End of Phase A) in the RVP Median Response Latency Score as Measured by CANTAB to End of Phase B
score on a scalePhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + Stimulant
Change From Baseline (End of Phase A) in the RVP Median Response Latency Score as Measured by CANTAB to End of Phase B-17.1 ± 5.36-2.89 ± 7.10
Statistical analysis
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · ANCOVA · p = 0.0849 (The p-value was derived from ANCOVA model, with treatment and study center as main effects and week 5 value as covariate, is used for change from week 5 comparisons.) · Mean difference (final values): -14.3 · 95% CI -30.5 to 1.98The difference between LS means derived from the ANCOVA model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
SecondaryChange From Baseline (End of Phase A) in RVP Total False Alarms Score as Measured by CANTAB to End of Phase B

RVP task tested continuous performance and visual sustained attention. In center of computer screen, digits from 2- 9 appear inside a white box in pseudorandom order at a rate of 100 digits per minute. Participants must touch press pad when they detect a series of target digit sequences (e.g., 2-4-6, 4-6-8, 3-5-7) which appeared at a rate of 9 sequences every 100 numbers. Data from RVP task were summarized in 3 ways: RVP A prime, RVP median response latency, and RVP total false alarms. False alarms were determined from number of times that participants responded outside response window of a target sequence during assessed part of test. Observed range for Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant is -26.0 to 13.00 (change from baseline) and for Phase B (Double-blind Randomization Phase): Placebo + Stimulant is -25.0 to 144.0 (change from baseline). Lower scores indicate better performance. ANCOVA model was used for analysis.

Time frame:
Baseline [end of Phase A (Week 5)] to Week 11
Reported as:
Least squares mean · score on a scale
Change From Baseline (End of Phase A) in RVP Total False Alarms Score as Measured by CANTAB to End of Phase B
score on a scalePhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + Stimulant
Change From Baseline (End of Phase A) in RVP Total False Alarms Score as Measured by CANTAB to End of Phase B0.12 ± 1.010.58 ± 1.34
Statistical analysis
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · ANCOVA · p = 0.7663 (The p-value was derived from ANCOVA model, with treatment and study center as main effects and week 5 value as covariate, is used for change from week 5 comparisons.) · Mean difference (final values): -0.46 · 95% CI -3.52 to 2.60The difference between LS means derived from the ANCOVA model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
SecondaryChange From Baseline (End of Phase A) in the Stop Signal Task (SST) Stop Signal Reaction Time (SSRT) Score as Measured by CANTAB to End of Phase B

In SST, an arrow pointing either left or right is displayed on computer screen. Participant responded to arrow by pressing corresponding button (i.e., left or right) on press pad. If an audio tone is presented when arrow is displayed, participant inhibited response. Proportion of successful stops, and median reaction time on Go trials was measured. SST SSRT was an estimate of length of time between go stimulus and stop stimulus at which participant was able to successfully inhibit response on 50% of trials and calculated from SST reaction time on Go trials measure and SST stop signal delay (SSD) 50% measure as \[reaction time on Go trials\] - \[SSD (50%)\], where SSD (50%) measure was calculated as arithmetic mean of measured SSD, or failed stop reaction time, from completed assessment stop trials. Observed change from baseline range for Phase B: Brexpiprazole + Stimulant: -204 to 237.0 and for Phase B: Placebo + Stimulant: -176 to 113.0. Lower scores indicate better performance.

Time frame:
Baseline [end of Phase A (Week 5)] to Week 11
Reported as:
Least squares mean · score on a scale
Change From Baseline (End of Phase A) in the Stop Signal Task (SST) Stop Signal Reaction Time (SSRT) Score as Measured by CANTAB to End of Phase B
score on a scalePhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + Stimulant
Change From Baseline (End of Phase A) in the Stop Signal Task (SST) Stop Signal Reaction Time (SSRT) Score as Measured by CANTAB to End of Phase B13.41 ± 5.12-4.10 ± 6.92
Statistical analysis
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · ANCOVA · p = 0.0298 (The p-value was derived from ANCOVA model, with treatment and study center as main effects and week 5 value as covariate, is used for change from week 5 comparisons.) · Mean difference (final values): 17.51 · 95% CI 1.73 to 33.29The difference between LS means derived from the ANCOVA model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
SecondaryChange From Baseline (End of Phase A) in the SST Proportion of Successful Stops Score as Measured by CANTAB to End of Phase B

SST measures participants ability to inhibit a response. An arrow pointing either left or right is displayed on computer screen. Participant responded to arrow by pressing corresponding button (i.e., left or right) on press pad. If an audio tone is presented when arrow is displayed, participant inhibited his/her response. Proportion of successful stops, and median reaction time on Go trials was measured. The proportion of successful stops is calculated as the number of times that the participant stopped successfully, divided by the total number of stop signals. Observed range for Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant: -0.40 to 0.40 (change from baseline) and for Phase B (Double-blind Randomization Phase): Placebo + Stimulant: -0.38 to 0.38 (change from baseline). Higher scores indicate a positive outcome for proportion of successful stops.

Time frame:
Baseline [end of Phase A (Week 5)] to Week 11
Reported as:
Least squares mean · score on a scale
Change From Baseline (End of Phase A) in the SST Proportion of Successful Stops Score as Measured by CANTAB to End of Phase B
score on a scalePhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + Stimulant
Change From Baseline (End of Phase A) in the SST Proportion of Successful Stops Score as Measured by CANTAB to End of Phase B-0.01 ± 0.010.01 ± 0.01
Statistical analysis
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · ANCOVA · p = 0.2563 (The p-value was derived from ANCOVA model, with treatment and study center as main effects and week 5 value as covariate, is used for change from week 5 comparisons.) · Mean difference (final values): -0.02 · 95% CI -0.05 to 0.01The difference between LS means derived from the ANCOVA model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
SecondaryChange From Baseline (End of Phase A) in SST Median Reaction Time Score on Go Trials as Measured by CANTAB to End of Phase B

SST measures participants ability to inhibit a response. An arrow pointing either left or right is displayed on computer screen. Participant responded to arrow by pressing corresponding button (i.e., left or right) on press pad. If an audio tone is presented when arrow is displayed, participant inhibited his/her response. Proportion of successful stops, and median reaction time on Go trials was measured. The median reaction time on Go trials is the median of the reaction time assessed on Go trials to which the participant responded correctly. Observed range for Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant: -277 to 266.0 (change from baseline) and for Phase B (Double-blind Randomization Phase): Placebo + Stimulant: -462 to 358.0 (change from baseline). Lower scores indicate better performance.

Time frame:
Baseline [end of Phase A (Week 5)] to Week 11
Reported as:
Least squares mean · score on a scale
Change From Baseline (End of Phase A) in SST Median Reaction Time Score on Go Trials as Measured by CANTAB to End of Phase B
score on a scalePhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + Stimulant
Change From Baseline (End of Phase A) in SST Median Reaction Time Score on Go Trials as Measured by CANTAB to End of Phase B-6.70 ± 8.39-1.03 ± 11.2
Statistical analysis
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · ANCOVA · p = 0.6644 (The p-value was derived from ANCOVA model, with treatment and study center as main effects and week 5 value as covariate, is used for change from week 5 comparisons.) · Mean difference (final values): -5.67 · 95% CI -31.4 to 20.06The difference between LS means derived from the ANCOVA model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
SecondaryChange From Baseline (End of Phase A) in WRAADDS Attention + Organization Subscale Score to End of Phase B

WRAADDS is used to measure the severity of symptoms in adults with ADHD. This structured interview consists of 28 items in 7 psychopathologic domains, which were rated by a clinical expert on a 0 to 2-point Likert scale. The psychopathologic 7 domains are inattention (6 items), impulsivity (3 items), and hyperactivity (3 items), disorganization (5 items), temper (3 items), affective lability (4 items), and emotional over-reactivity (4 items). The scale rated individual items from 0 to 2 (0=not present, 1=mild, 2=clearly present). The score for attention + organization subscale score ranges from 0-22, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The ANCOVA method was used for analysis.

Time frame:
Baseline [end of Phase A (Week 5)] to Week 11
Reported as:
Least squares mean · score on a scale
Change From Baseline (End of Phase A) in WRAADDS Attention + Organization Subscale Score to End of Phase B
score on a scalePhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + Stimulant
Change From Baseline (End of Phase A) in WRAADDS Attention + Organization Subscale Score to End of Phase B-1.47 ± 0.17-1.42 ± 0.22
Statistical analysis
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · ANCOVA · p = 0.8418 (The p-value was derived from ANCOVA model, with treatment and study center as main effects and week 5 value as covariate, is used for change from week 5 comparisons.) · Mean difference (final values): -0.05 · 95% CI -0.56 to 0.45The difference between LS means derived from the ANCOVA model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
SecondaryChange From End of Phase A (Week 5 Visit) to End of Phase B (Week 11 Visit) in WRAADDS Hyperactivity + Impulsivity Subscale Score to End of Phase B

WRAADDS is used to measure the severity of symptoms in adults with ADHD. This structured interview consists of 28 items in 7 psychopathologic domains, which were rated by a clinical expert on a 0 to 2-point Likert scale. The psychopathologic 7 domains are inattention (6 items), impulsivity (3 items), and hyperactivity (3 items), disorganization (5 items), temper (3 items), affective lability (4 items), and emotional over-reactivity (4 items). The scale rated individual items from 0 to 2 (0=not present, 1=mild, 2=clearly present). The score for hyperactivity + impulsivity subscale score ranges from 0-12, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The ANCOVA model was used for analysis.

Time frame:
Baseline [end of Phase A (Week 5)] to Week 11
Reported as:
Least squares mean · score on a scale
Change From End of Phase A (Week 5 Visit) to End of Phase B (Week 11 Visit) in WRAADDS Hyperactivity + Impulsivity Subscale Score to End of Phase B
score on a scalePhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + Stimulant
Change From End of Phase A (Week 5 Visit) to End of Phase B (Week 11 Visit) in WRAADDS Hyperactivity + Impulsivity Subscale Score to End of Phase B-1.27 ± 0.14-1.01 ± 0.19
Statistical analysis
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · ANCOVA · p = 0.2513 (The p-value was derived from ANCOVA model, with treatment and study center as main effects and week 5 value as covariate, is used for change from week 5 comparisons.) · Mean difference (final values): -0.26 · 95% CI -0.69 to 0.18The difference between LS means derived from the ANCOVA model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
SecondaryChange From Baseline (End of Phase A) in WRAADDS Temper + Mood Lability + Emotional Over-reactivity Subscale Score to End of Phase B

WRAADDS is used to measure the severity of symptoms in adults with ADHD. This structured interview consists of 28 items in 7 psychopathologic domains, which were rated by a clinical expert on a 0 to 2-point Likert scale. The psychopathologic 7 domains are inattention (6 items), impulsivity (3 items), and hyperactivity (3 items), disorganization (5 items), temper (3 items), affective lability (4 items), and emotional over-reactivity (4 items). The scale rated individual items from 0 to 2 (0=not present, 1=mild, 2=clearly present). The score for temper + mood Lability + emotional over-reactivity subscale score ranges from 0-22, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The ANCOVA model was used for analysis.

Time frame:
Baseline [end of Phase A (Week 5)] to Week 11
Reported as:
Least squares mean · score on a scale
Change From Baseline (End of Phase A) in WRAADDS Temper + Mood Lability + Emotional Over-reactivity Subscale Score to End of Phase B
score on a scalePhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + Stimulant
Change From Baseline (End of Phase A) in WRAADDS Temper + Mood Lability + Emotional Over-reactivity Subscale Score to End of Phase B-1.24 ± 0.20-1.35 ± 0.26
Statistical analysis
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · ANCOVA · p = 0.7037 (The p-value was derived from ANCOVA model, with treatment and study center as main effects and week 5 value as covariate, is used for change from week 5 comparisons.) · Mean difference (final values): 0.11 · 95% CI -0.48 to 0.71The difference between LS means derived from the ANCOVA model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
SecondaryMean CGI-I Score at Each Timepoint in Phase B

The CGI-I permits a global evaluation of the participant's improvement over time. The CGI-I is a 8-point scale ranging from 0 to 7 where 0=not assessed, 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse and 7=very much worse. The CGI-I is completed by the clinician and assesses the participant's improvement relative to the symptoms at Baseline. The Cochran-Mantel-Haenszel model was used for analysis.

Time frame:
Weeks 6, 7, 8, 9, 10 and 11
Reported as:
Mean · score on a scale
Mean CGI-I Score at Each Timepoint in Phase B
score on a scalePhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + Stimulant
Week 63.19 ± 0.813.12 ± 0.77
Week 73.04 ± 0.883.08 ± 0.80
Week 82.93 ± 0.962.88 ± 1.01
Week 92.82 ± 1.022.81 ± 1.03
Week 102.80 ± 0.992.76 ± 1.07
Week 112.68 ± 1.062.69 ± 1.17
Statistical analysis
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.7572 (The p-value was derived from CMH row mean scores differ test controlling for study center.) · Mean difference (final values): 0.03 · 95% CI -0.17 to 0.23The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.6132 (The p-value was derived from CMH row mean scores differ test controlling for study center.) · Mean difference (final values): -0.06 · 95% CI -0.28 to 0.17The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.9312 (The p-value was derived from CMH row mean scores differ test controlling for study center.) · Mean difference (final values): 0.01 · 95% CI -0.25 to 0.27The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.8073 (The p-value was derived from CMH row mean scores differ test controlling for study center.) · Mean difference (final values): -0.03 · 95% CI -0.30 to 0.24The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.9168 (The p-value was derived from CMH row mean scores differ test controlling for study center.) · Mean difference (final values): 0.01 · 95% CI -0.26 to 0.29The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.7432 (The p-value was derived from CMH row mean scores differ test controlling for study center.) · Mean difference (final values): -0.05 · 95% CI -0.34 to 0.25The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
SecondaryPercentage of Participants With CAARS-O:SV ADHD Symptoms Response Rate in Phase B

Response was defined as ≥ 30% reduction in CAARS-O:SV ADHD Symptoms Total Score (18 items) from end of Phase A (Week 5 visit). An 18-item ADHD Symptoms Total Score consisted of the combined score for the Inattentive Symptoms and Hyperactive/Impulsive Symptoms subscales. The CAARS-O:SV was designed to measure a cross-section of ADHD-related symptoms and behaviors in adults using observer and self-report scales. Total ADHD Symptoms Score (18 items) consisted of the combined score for the inattentive symptoms and hyperactive/impulsive symptoms subscales and is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) for a total score ranging from of 0 to 54, higher scores indicate worsening of symptoms.

Time frame:
Weeks 6, 7, 8, 9, 10 and 11
Reported as:
Number · percentage of participants
Percentage of Participants With CAARS-O:SV ADHD Symptoms Response Rate in Phase B
percentage of participantsPhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + Stimulant
Week 615.012.8
Week 724.224.4
Week 828.833.3
Week 935.941.0
Week 1037.944.9
Week 1145.150.0
Statistical analysis
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.6014 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 1.20 · 95% CI 0.60 to 2.42The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.9225 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 1.02 · 95% CI 0.64 to 1.63The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.4803 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 0.86 · 95% CI 0.58 to 1.30The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.5876 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 0.91 · 95% CI 0.65 to 1.27The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.3727 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 0.87 · 95% CI 0.64 to 1.18The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.6265 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 0.93 · 95% CI 0.71 to 1.23The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
SecondaryPercentage of Participants With CAARS-O:SV ADHD Symptoms Remission Rate in Phase B

Remission was defined as CAARS-O:SV ADHD Symptoms Total Score (18 items) of ≤ 18 and a ≥ 30% reduction in CAARS-O:SV ADHD Symptoms Total Score (18 items) from end of Phase A (Week 5 visit). An 18-item ADHD Symptoms Total Score consisted of the combined score for the Inattentive Symptoms and Hyperactive/Impulsive Symptoms subscales. The CAARS-O:SV was designed to measure a cross-section of ADHD-related symptoms and behaviors in adults using observer and self-report scales. Total ADHD Symptoms Score (18 items) consisted of the combined score for the inattentive symptoms and hyperactive/impulsive symptoms subscales and is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) for a total score ranging from of 0 to 54, higher scores indicate worsening of symptoms. The Cochran-Mantel-Haenszel model was used for analysis.

Time frame:
Weeks 6, 7, 8, 9, 10 and 11
Reported as:
Number · percentage of participants
Percentage of Participants With CAARS-O:SV ADHD Symptoms Remission Rate in Phase B
percentage of participantsPhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + Stimulant
Week 67.196.41
Week 712.412.8
Week 819.019.2
Week 920.923.1
Week 1025.528.2
Week 1127.533.3
Statistical analysis
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.8586 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 1.10 · 95% CI 0.40 to 3.03The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.8984 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 0.95 · 95% CI 0.46 to 1.99The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.9778 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 0.99 · 95% CI 0.57 to 1.74The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.7315 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 0.92 · 95% CI 0.56 to 1.50The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.6518 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 0.90 · 95% CI 0.57 to 1.42The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.3472 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 0.82 · 95% CI 0.55 to 1.23The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
SecondaryPercentage of Participants With CAARS-S:SV ADHD Symptoms Response Rate in Phase B

Response was defined as ≥ 30% reduction in CAARS-S:SV ADHD Symptoms Total Score (18 items) from end of Phase A (Week 5 visit). The CAARS-S:SV is a 30 items scale with 3 subscales inattention (9 items), hyperactivity-impulsivity (9 items), and ADHD index (12 items). Total ADHD Symptoms Score (18 items) consisted of the combined score for the Inattentive Symptoms and Hyperactive/Impulsive Symptoms subscales is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) for total score ranging from of 0 to 54, higher scores indicate worsening of symptoms. The Cochran-Mantel-Haenszel model was used for analysis.

Time frame:
Weeks 6, 7, 8, 9, 10 and 11
Reported as:
Number · percentage of participants
Percentage of Participants With CAARS-S:SV ADHD Symptoms Response Rate in Phase B
percentage of participantsPhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + Stimulant
Week 611.812.8
Week 718.315.4
Week 821.621.8
Week 929.429.5
Week 1025.532.1
Week 1131.437.2
Statistical analysis
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.9577 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 0.98 · 95% CI 0.44 to 2.16The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.5864 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 1.19 · 95% CI 0.63 to 2.27The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.8723 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 0.96 · 95% CI 0.57 to 1.60The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.9872 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 1.00 · 95% CI 0.65 to 1.52The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.3171 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 0.80 · 95% CI 0.52 to 1.23The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.4782 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 0.87 · 95% CI 0.60 to 1.27The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
SecondaryPercentage of Participants With CAARS-S:SV ADHD Symptoms Remission Rate in Phase B

Remission was defined as CAARS-S:SV ADHD Symptoms Total Score (18 items) of ≤ 18 and a ≥ 30% reduction in CAARS-S:SV ADHD Symptoms Total Score (18 items) from end of Phase A (Week 5 visit). The CAARS-S:SV is a 30 items scale with 3 subscales inattention (9 items), hyperactivity-impulsivity (9 items), and ADHD index (12 items). Total ADHD Symptoms Score (18 items) consisted of the combined score for the Inattentive Symptoms and Hyperactive/Impulsive Symptoms subscales is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) for total score ranging from of 0 to 54, higher scores indicate worsening of symptoms. The Cochran-Mantel-Haenszel model was used for analysis.

Time frame:
Weeks 6, 7, 8, 9, 10 and 11
Reported as:
Number · percentage of participants
Percentage of Participants With CAARS-S:SV ADHD Symptoms Remission Rate in Phase B
percentage of participantsPhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + Stimulant
Week 68.507.69
Week 712.412.8
Week 815.715.4
Week 920.920.5
Week 1020.919.2
Week 1124.225.6
Statistical analysis
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.7232 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 1.19 · 95% CI 0.45 to 3.19The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.9860 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 0.99 · 95% CI 0.46 to 2.13The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.9858 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 1.01 · 95% CI 0.52 to 1.95The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.9466 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 1.02 · 95% CI 0.58 to 1.78The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.6962 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 1.12 · 95% CI 0.63 to 2.00The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.7637 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 0.93 · 95% CI 0.57 to 1.51The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
SecondaryPercentage of Participants With CGI-I Response Rate in Phase B

Response was defined as a CGI-I score of 1 or 2 (very much improved or much improved). The CGI-I permits a global evaluation of the participant's improvement over time. The CGI-I is a 8-point scale ranging from 0 to 7 where 0=not assessed, 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse and 7=very much worse. The Cochran-Mantel-Haenszel model was used for analysis.

Time frame:
Weeks 6, 7, 8, 9, 10 and 11
Reported as:
Number · percentage of participants
Percentage of Participants With CGI-I Response Rate in Phase B
percentage of participantsPhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + Stimulant
Week 618.315.4
Week 723.517.9
Week 831.430.8
Week 937.941.0
Week 1040.539.7
Week 1144.444.9
Statistical analysis
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.3631 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 1.30 · 95% CI 0.73 to 2.33The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.2786 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 1.35 · 95% CI 0.78 to 2.35The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.7062 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 1.08 · 95% CI 0.72 to 1.62The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.7844 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 0.95 · 95% CI 0.67 to 1.35The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.6940 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 1.07 · 95% CI 0.77 to 1.48The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.
  • Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant vs Phase B (Double-blind Randomization Phase): Placebo + Stimulant · Cochran-Mantel-Haenszel · p = 0.8697 (The p-value was derived from CMH general association test controlling for study center.) · Risk ratio (rr): 1.03 · 95% CI 0.76 to 1.39The difference between LS means derived from the CMH model. This comparison was tested for statistical significance at a 0.05 (two-sided) significance level.

Adverse events

Collected over From first dose through 30 days after last dose of study drug (Up to approximately Week 15). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase A (Single-blind Prospective Treatment Phase): Placebo + Stimulant0/733 (0%)0/733 (0%)440/733 (60%)
Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant0/155 (0%)0/155 (0%)32/155 (20.6%)
Phase B (Double-blind Randomization Phase): Placebo + Stimulant0/80 (0%)2/80 (2.5%)25/80 (31.3%)
Phase A+ (Single-blind Phase A Responders and Non-responders): Placebo + Stimulant0/339 (0%)0/339 (0%)17/339 (5%)
Most frequent serious events
Most frequent serious events
EventPhase A (Single-blind Prospective Treatment Phase): Placebo + StimulantPhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + StimulantPhase A+ (Single-blind Phase A Responders and Non-responders): Placebo + Stimulant
PneumoniaInfections and infestations0/7330/1551/800/339
Urinary tract infectionInfections and infestations0/7330/1551/800/339
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPhase A (Single-blind Prospective Treatment Phase): Placebo + StimulantPhase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + StimulantPhase A+ (Single-blind Phase A Responders and Non-responders): Placebo + Stimulant
Decreased AppetiteMetabolism and nutrition disorders155/7330/1550/800/339
HeadacheNervous system disorders128/73311/15510/800/339
Dry MouthGastrointestinal disorders113/7330/1550/800/339
InsomniaPsychiatric disorders85/7330/1550/800/339
InsomniaPsychiatric disorders0/73313/1551/800/339
IrritabilityGeneral disorders57/7330/1550/800/339
Weight decreasedInvestigations47/7335/1556/800/339
NauseaGastrointestinal disorders51/7330/1550/800/339
DiarrhoeaGastrointestinal disorders0/7333/1555/800/339
Upper respiratory tract infectionInfections and infestations0/7335/1555/800/339

Baseline characteristics

Randomized Sample consisted of all participants who were randomized in Phase B. Phase A+ Sample consisted of all non-randomized participants who were Phase A Responders or Phase A Non-responders, and who continued on Stimulant + single-blind placebo beyond Week 5. As pre-specified in the protocol and statistical analysis plan (SAP) the data is reported for Phase B and Phase A+ participants.

Age, Continuous
Age, Continuous(years)Phase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + StimulantPhase A+ (Single-blind Phase A Responders and Non-responders): Placebo + StimulantTotal
Mean36.0 (18.0 to 55.0)33.6 (18.0 to 55.0)33.6 (18.0 to 55.0)34.4 (18.0 to 55.0)
Sex: Female, Male
Sex: Female, Male(Participants)Phase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + StimulantPhase A+ (Single-blind Phase A Responders and Non-responders): Placebo + StimulantTotal
Female7938164281
Male7642175293
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + StimulantPhase A+ (Single-blind Phase A Responders and Non-responders): Placebo + StimulantTotal
Hispanic or Latino19104877
Not Hispanic or Latino13669288493
Unknown or Not Reported0134
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + StimulantPhase A+ (Single-blind Phase A Responders and Non-responders): Placebo + StimulantTotal
American Indian or Alaska Native1146
Asian30912
Native Hawaiian or Other Pacific Islander0000
Black or African American9103857
White14065281486
More than one race0000
Unknown or Not Reported24713
CAARS-O:SV ADHD Symptoms Total Score (18 items)
CAARS-O:SV ADHD Symptoms Total Score (18 items)(score on a scale)Phase B (Double-blind Randomization Phase): Brexpiprazole + StimulantPhase B (Double-blind Randomization Phase): Placebo + StimulantPhase A+ (Single-blind Phase A Responders and Non-responders): Placebo + StimulantTotal
Mean32.94 (24.00 to 47.00)33.99 (24.00 to 52.00)40.1 (30.00 to 54.00)35.67 (24.00 to 54.00)
08

Study locations

35 sites
  • Little Rock, Arkansas, United States
  • Beverly Hills, California, United States
  • Irvine, California 92612, United States
  • Pasadena, California, United States
  • San Francisco, California, United States
  • Bradenton, Florida, United States
  • Jacksonville, Florida, United States
  • Maitland, Florida, United States
  • North Miami, Florida, United States
  • Orlando, Florida, United States
  • South Miami, Florida 33173, United States
  • Atlanta, Georgia, United States
  • Smyrna, Georgia, United States
  • Indianapolis, Indiana, United States
  • Overland Park, Kansas, United States
  • Rochester Hills, Michigan, United States
  • Saint Charles, Missouri, United States
  • Cherry Hill, New Jersey, United States
  • Willingboro, New Jersey, United States
  • New York, New York, United States
  • Chapel Hill, North Carolina, United States
  • Durham, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Dayton, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Portland, Oregon, United States
  • Philadelphia, Pennsylvania, United States
  • Memphis, Tennessee, United States
  • Austin, Texas, United States
  • Houston, Texas, United States
  • Salt Lake City, Utah, United States
  • Woodstock, Vermont, United States
  • Herndon, Virginia, United States
  • Bellevue, Washington, United States
  • Seattle, Washington, United States
09

References and documents

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2010 to primary completion in Jun 2011, 15 months.

Results were first posted in Feb 2023, 11 years 7 months after primary completion. A results delay was requested in Oct 2012.

Of 24 industry-sponsored phase 2 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's 15 months is above that.

Counting every sponsor, half of 40 studies reached it within 15 months; a quarter within 5 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2010
First posted
Feb 24, 2010
StartActual
Mar 16, 2010
Primary completionActual
Jun 20, 2011
CompletionActual
Jun 20, 2011
Results delay requested
Oct 23, 2012
Results first posted
Feb 2, 2023
Last update
Feb 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01074294
Responsible party
Sponsor
First posted
Feb 24, 2010
Start date
Mar 16, 2010
Primary completion
Jun 20, 2011
Completion
Jun 20, 2011
Results posted
Feb 2, 2023
Last update
Feb 2, 2023

Study contacts

Study Director
study director · Otsuka Pharmaceutical Development & Commercialization, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion